Association of combination statin and antihypertensive therapy with reduced Alzheimer’s disease and related dementia risk

Douglas Barthold; Geoffrey Joyce; Roberta Diaz Brinton; Whitney Wharton; Patrick Gavin Kehoe; Julie Zissimopoulos

doi:10.1371/journal.pone.0229541

. 2020 Mar 4;15(3):e0229541. doi: 10.1371/journal.pone.0229541

Association of combination statin and antihypertensive therapy with reduced Alzheimer’s disease and related dementia risk

Douglas Barthold ^1,^*, Geoffrey Joyce ², Roberta Diaz Brinton ³, Whitney Wharton ^4,⁵, Patrick Gavin Kehoe ⁶, Julie Zissimopoulos ⁷

Editor: Tarek K Rajji⁸

¹Department of Pharmacy, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, United States of America

²School of Pharmacy, Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, United States of America

³Center for Innovation in Brain Science, University of Arizona Health Sciences, Tuscon, AZ, United States of America

⁴School of Nursing, Emory University, Atlanta, GA, United States of America

⁵Department of Neurology, Emory University School of Medicine, Atlanta, GA, United States of America

⁶Bristol Medical School, Translational Health Sciences, University of Bristol, Bristol, United Kingdom

⁷Price School of Public Policy, Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, United States of America

⁸University of Toronto, CANADA

Competing Interests: Partial financial support for this research was provided by Amgen. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The company had no role in any stage of the research process. The concept, design, acquisition, analysis, and interpretation of data, manuscript drafting, and revisions, were completed without any involvement from the company.

^✉

* E-mail: barthold@uw.edu

Roles

Douglas Barthold: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing

Geoffrey Joyce: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

Roberta Diaz Brinton: Conceptualization, Funding acquisition, Investigation, Writing – review & editing

Whitney Wharton: Conceptualization, Investigation, Writing – review & editing

Patrick Gavin Kehoe: Conceptualization, Investigation, Writing – review & editing

Julie Zissimopoulos: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

Tarek K Rajji: Editor

PMCID: PMC7055882 PMID: 32130251

Abstract

Background

Hyperlipidemia and hypertension are modifiable risk factors for Alzheimer’s disease and related dementias (ADRD). Approximately 25% of adults over age 65 use both antihypertensives (AHTs) and statins for these conditions. While a growing body of evidence found statins and AHTs are independently associated with lower ADRD risk, no evidence exists on simultaneous use for different drug class combinations and ADRD risk. Our primary objective was to compare ADRD risk associated with concurrent use of different combinations of statins and antihypertensives.

Methods

In a retrospective cohort study (2007–2014), we analyzed 694,672 Medicare beneficiaries in the United States (2,017,786 person-years) who concurrently used both statins and AHTs. Using logistic regression adjusting for age, socioeconomic status and comorbidities, we quantified incident ADRD diagnosis associated with concurrent use of different statin molecules (atorvastatin, pravastatin, rosuvastatin, and simvastatin) and AHT drug classes (two renin-angiotensin system (RAS)-acting AHTs, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin-II receptor blockers (ARBs), vs non-RAS-acting AHTs).

Findings

Pravastatin or rosuvastatin combined with RAS-acting AHTs reduce risk of ADRD relative to any statin combined with non-RAS-acting AHTs: ACEI+pravastatin odds ratio (OR) = 0.942 (CI: 0.899–0.986, p = 0.011), ACEI+rosuvastatin OR = 0.841 (CI: 0.794–0.892, p<0.001), ARB+pravastatin OR = 0.794 (CI: 0.748–0.843, p<0.001), ARB+rosuvastatin OR = 0.818 (CI: 0.765–0.874, p<0.001). ARBs combined with atorvastatin and simvastatin are associated with smaller reductions in risk, and ACEI with no risk reduction, compared to when combined with pravastatin or rosuvastatin. Among Hispanics, no combination of statins and RAS-acting AHTs reduces risk relative to combinations of statins and non-RAS-acting AHTs. Among blacks using ACEI+rosuvastatin, ADRD odds were 33% lower compared to blacks using other statins combined with non-RAS-acting AHTs (OR = 0.672 (CI: 0.548–0.825, p<0.001)).

Conclusion

Among older Americans, use of pravastatin and rosuvastatin to treat hyperlipidemia is less common than use of simvastatin and atorvastatin, however, in combination with RAS-acting AHTs, particularly ARBs, they may be more effective at reducing risk of ADRD. The number of Americans with ADRD may be reduced with drug treatments for vascular health that also confer effects on ADRD.

Introduction

Alzheimer’s disease and related dementias (ADRD) are a large and growing public health issue. There are approximately 7 million individuals aged 65 and older living with ADRD in the United States, and this number is projected to grow to 12 million by 2040 [1]. With no disease-modifying treatments for ADRD, there has been increased global attention on prevention and risk reduction of ADRD by maintenance of a healthy lifestyle and management of diseases such as hypertension and dyslipidemia [2–5]. A reduction in risk of ADRD would bring significant health and financial benefits to individuals, societies, and families [6].

Antihypertensive therapies are effective pharmaceutical treatments for hypertension, and statins for dyslipidemia. Statins are hypothesized to act on Alzheimer’s disease (AD) pathology through their effect on cholesterol as well as through other nonlipid effects such as reduced inflammation, although heterogeneity in molecular structure, efficacy, and pharmacokinetics across statins suggests potential variability in effects [7–12]. Randomized controlled trials and reviews in this area have failed to find a beneficial effect of statins on AD, although limitations of these studies (e.g., short follow-up periods, non-representative samples, and removal of hyperlipidemic subjects) are well recognized [13–15]. There is, however, a growing body of observational evidence showing that statins are associated with reduced ADRD risk [16–22], including our own work that featured robust control for confounding in a large and representative dataset [16]. Recent evidence also suggests that some subgroups may be more responsive to statin therapy than others [23, 24]. Though potential influence of statins on AD pathology is still unclear, some trials suggest statin-related attenuation of tau in middle age participants, which aligns with the findings from a community based-autopsy cohort [25, 26].

Systematic analysis of observational, randomized controlled trials, and meta-analyses found AHT treatment was protective against cognitive decline and incident dementia [27–30]. Several studies have implicated the renin-angiotensin system (RAS) in AD, in particular over-activation of the classical hypertension-promoting RAS (cRAS), and more recently dysfunction of the regulatory RAS (rRAS), which ordinarily regulates cRAS activity [31–37]. A recent study confirmed these results and reported that RAS AHT users (vs. other AHT users) exhibited fewer neurofibrillary tangles in predetermined brain regions involved in AD [38]. These findings are consistent with hypotheses that therapeutic classes of AHTs operating to reduce RAS activity (i.e., angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs)), may affect AD differently than other AHT drug classes (e.g., calcium channel blockers, beta blockers, loop diuretics, or thiazide diuretics) [39–41]. Moreover, in vitro and animal studies of AD show that ARBs were more protective than ACEIs because of ACEI’s potential role in amyloid-beta degradation, and in Tg2576 mice that enhancement of rRAS can prevent and reverse cognitive decline and reduce amyloid-beta pathology [35, 40, 42, 43]. Our recent observational study confirmed this relationship in a longitudinal, population study [44].

Approximately one quarter of older Americans used both a statin and an AHT in 2014. Despite the high prevalence of use and hypothesized variation in effects across different types of statins and AHTs, there are no existing analyses of the association of use of specific combinations of AHT and statins and ADRD risk. The widespread use of these drugs increases the importance of analyses examining the combinations of therapies that are associated with the greatest and least reduction in ADRD risk and for specific populations. The purpose of this study is to use data from a large population-based cohort to examine the hypothesis that some combinations of statins and AHTs may be more protective against ADRD onset than others, and analyze variation by sex and race/ethnicity in order to inform about the potential for population-specific health benefits.

Methods

Data

We examined the medical and pharmacy claims of a random 20% sample of Medicare beneficiaries, aged 67 and higher, enrolled in traditional Medicare (fee-for-service) from 2007 to 2014. Medicare is publicly funded health insurance in the United States for individuals aged 65 and higher, as well younger beneficiaries with certain permanent disabilities. As of 2018, there were approximately 60 million enrollees in Medicare, two thirds of whom had traditional (fee-for-service) Medicare (as opposed to Medicare Advantage, a privately administered alternative) [45]. Traditional Medicare tends to enroll slightly less healthy beneficiaries than Medicare Advantage, but still comprise a majority of older adults in the United States, with nationwide representativeness [45]. We linked claims from Medicare Parts A (inpatient care), B (outpatient care), and D (prescription drugs) to enrollment files that included beneficiaries’ characteristics. Part D claims include key elements related to prescription drug utilization, while Parts A and B claims capture include detailed diagnosis and procedure codes (International Classification of Diseases, Ninth Revision (ICD-9)). These data were further supplemented with claims histories from the Chronic Conditions Warehouse. Institutional review board approval was granted by the University of Southern California University Park IRB, which granted a waiver of participant consent under 45 CFR 46.116(d).

Study sample

The study sample consisted of person-years for Medicare beneficiaries age 67 and older. In each person-year, we required observation for a minimum of three years (that year and the previous two) with consecutive fee-for-service enrollment, Part D enrollment, and no death. Individuals were required to have used both an AHT and a statin for the two previous years, have no prior ADRD diagnoses, and no prior use of AD specific medications (acetylcholinesterase inhibitors (AChEIs) or memantine). ICD-9 codes are specified in S1 Appendix. The analytic sample consisted of 694,672 unique beneficiaries, followed for a total of 2,017,786 person-years (1,241,491 for females, and 776,295 for males). Table 1 shows the characteristics of the analytic sample.

Table 1. Characteristics of combination statin and AHT users in 2009–2014 Medicare claims data.

	RAS + any statin	Non-RAS AHT + any statin	ACEI + ator	ACEI + pra	ACEI + rosu	ACEI + sim	ARB + ator	ARB + pra	ARB + rosu	ARB + sim
ADRD	2.07%	2.64%	2.18%	2.03%	1.63%	2.16%	2.02%	1.94%	1.62%	2.02%
Age	77.3	78.0	77.2	77.2	76.2	77.1	77.6	77.8	76.7	77.6
Female	61%	63%	56%	60%	56%	57%	66%	70%	67%	68%
White	83%	86%	84%	86%	84%	85%	78%	82%	78%	79%
Black	6%	6%	6%	7%	7%	6%	7%	7%	6%	7%
Hispanic	6%	4%	6%	4%	6%	5%	7%	5%	8%	7%
Other race	5%	4%	4%	3%	3%	3%	9%	6%	8%	7%
% HS grad	76%	76%	76%	75%	75%	76%	76%	76%	75%	76%
Median income	$55,745	$55,919	$56,728	$53,436	$54,187	$54,208	$59,299	$55,548	$56,784	$56,319
# physician visits	9.5	9.9	9.1	9.2	9.9	8.7	10.7	10.8	11.6	10.1
HCC	1.25	1.33	1.26	1.24	1.25	1.24	1.28	1.26	1.26	1.26
AMI	9%	9%	10%	8%	10%	9%	8%	7%	8%	7%
ATF	18%	23%	18%	19%	18%	17%	18%	19%	17%	17%
Diabetes	53%	40%	52%	51%	54%	53%	55%	52%	57%	54%
Stroke	16%	18%	16%	17%	16%	16%	17%	17%	17%	16%
Beneficiaries	507,304	279,398	92,551	48,545	35,128	173,653	60,569	29,250	27,259	95,007
Observations	1,387,009	630,777	214,734	106,203	78,620	435,902	140,609	62,749	61,080	231,174

Open in a new tab

Sample of 2009–2014 Medicare person-years with 90 possession days and 2 claims of both an AHT and a statin in both years t-1 and t-2. RAS (renin-angiotensin system) AHTs are antihypertensive (AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs). Non-RAS acting AHTs are beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics. Statins are atorvastatin, pravastatin, rosuvastatin, and simvastatin. Sample restricted to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior ADRD diagnoses, and no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine. Abbrevations: ADRD (Alzheimer's disease and related dementias), HS (high school), HCC (Hierarchical Condition Category index), AMI (acute myocardial infarction), ATF (atrial fibrillation).

Measuring statin and AHT exposure

We identified AHT and statin use in Medicare Part D prescription drug claims (2007–2013). AHT use was for the following classes: angiotensin-converting enzyme inhibitors (ACEI), angiotensin-II receptor blockers (ARB), beta-blockers (BBL), calcium channel blockers (CCB), loop diuretics (LDs), and thiazide-like diuretics (TDs). Statin use was for the following molecules: atorvastatin, pravastatin, rosuvastatin, and simvastatin, which were the four most commonly used molecules in these data. We defined combination AHT and statin users as any individual with 90 days supply and at least two claims in a year for both types of drugs for the two previous years. This threshold was chosen as the minimum necessary to ensure regular use of the drug during the exposure period, and is consistent with the definitions used in earlier evidence [44]. We examined robustness of results to other definitions of use: 180 days and 2 claims, 270 days and 2 claims.

Study design

In a retrospective cohort design, we compared onset of ADRD separately for RAS-acting ACEI and ARB therapies combined with each different molecule of statin, to onset among persons using other combinations of non-RAS acting AHTs and statins. Onset of ADRD was measured using index date of ADRD diagnosis and we required an ADRD index diagnosis to be verified with either a second ADRD diagnosis code or ‘dementia specified elsewhere’ diagnosis code in a subsequent claim within the study period (2009–2014). Measurement error in the timing of ADRD diagnosis is unlikely to bias our results because the same error exists for subjects in both the exposure and comparator groups. To mitigate concern that imminent ADRD onset could lead to poor adherence or discontinuation of AHT use, we designated years t-1 and t-2 as the drug exposure years, prior to assessing ADRD risk in year t. For example, we relate AHT/statin use in 2007–2008 to ADRD risk in 2009; in the absence of an ADRD diagnosis, the same individual remains in the sample and their AHT/statin use in 2008–2009 is related to their ADRD incidence in 2010, and further, as long as they continue to meet the inclusion/exclusion criteria. Sex and race/ethnicity specific analyses use only members of the same sex or race/ethnicity as the comparison group; thus estimated differences in association across combinations is attributed to the drugs and not due to unobserved differences across sex or race/ethnicity.

Statistical analyses

We examined the association of combination AHT and statin use (in years t-1 and t-2) and incident ADRD (year t), during the years 2009 to 2014. We used multivariable logistic regression to control for the potentially confounding roles of age, age squared, sex, race, proxy measures of socio-economic status (high school graduation rate within the beneficiary’s zip code (quartiles), zip code median income (quartiles)), years since hypertension and hyperlipidemia diagnoses, comorbidity index (quartiles), number of physician visits (quartiles), and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial infarction, and stroke. Time-varying covariates were measured in year t-1. Health status was measured with past diagnosis of key comorbidities, as well as the Centers for Medicaid and Medicare Services-Hierarchical Condition Category (CMS-HCC), an index based on health status from diagnostic data and demographics, in which higher numbers indicate worse health. The CMS uses this index to predict health expenditures in the next year, and it correlates highly with mortality [46]. We used years since hypertension and hyperlipemia diagnoses, as measured by the Chronic Conditions Warehouse (CCW) as far back as 1999, to control for unobserved AHT and statin use in the years prior to Medicare Part D enactment in 2006. Race/ethnicity was determined with the beneficiary race code in CMS enrollment data, and with the application of a name-based identification algorithm from the Research Triangle Institute [47]. Standard errors were clustered at the county level. We ran analyses for the sample as a whole, as well as for each sex and for different racial/ethnic populations.

Results

Table 1 depicts the characteristics of our analytic sample. The annual ADRD incidence rate in this sample is 2.07% among persons using a RAS-acting AHT and any statin, and 2.64% among persons using a non-RAS-acting AHT and any statin. Generally, rates were lower persons using ARBs compared to ACEI with the exception of no difference in rates among persons using them in combination with rosuvastatin. Those using a RAS-acting AHT were younger, more likely to be male, non-white, and have a lower mean HCC score. There were no differences in percent high school graduate or median income. ACEI users compared to ARB users, across statin types, are about 0.5 years younger, more likely to be male, white, and have fewer physician visits, and lower HCC scores. There were no differences in percent high school graduate or median income.

Fig 1 reports odd ratios (ORs) and 95% confidence intervals from logistic regressions of ADRD incidence that adjust for the patient and setting characteristics described above. Compared to individuals using statins combined with non-RAS AHTs, use of pravastatin and rosuvastatin in combination of ARB or ACEI was associated with reduced risk of ADRD (ACEI+pravastatin OR = 0.942 (CI: 0.899–0.986, p = 0.011), ACEI+rosuvastatin OR = 0.841 (CI: 0.794–0.892, p<0.001), ARB+pravastatin OR = 0.794 (CI: 0.748–0.843, p<0.001), ARB+rosuvastatin OR = 0.818 (CI: 0.765–0.874, p<0.001)). There was no reduced risk associated with ACEI use and either atorvastatin or simvastatin, but a reduced risk when combined with ARBs (ARB+atorvastatin OR = 0.896 (CI: 0.861–0.932, p<0.001), ARB+simvastatin OR = 0.877 (CI: 0.848–0.908, p<0.001)).

Table 2 reports results of ORs separately for men and women. Combined use of ACEIs with three statins (atorvastatin, simvastatin, and pravastatin), compared to combined use statins and non-RAS-acting AHTs, was not associated with reduced ADRD risk among women. ACEI+rosuvastatin and ARB+rosuvastatin were associated with lower odds of ADRD among women (ACEI+rosuvastatin OR = 0.832 (CI: 0.776–0.892, p<0.001), ARB+rosuvastatin OR = 0.833 (CI: 0.774–0.895, p<0.001). Among men, with the exception of simvastatin, combine use of any statin and either ACEI or ARB was associated with lower odds of ADRD incidence.

Table 2. Adjusted odds ratios of ADRD incidence associated with use of statin-AHT combinations, relative to users of other statin-AHT combinations.

Statin	AHT		Female	Male	White	Black	Hispanic
Ator	ACEI	OR	1.021	0.916	0.984	0.983	1.009
		CI	(0.983–1.060)	(0.868–0.966)	(0.951–1.019)	(0.864–1.117)	(0.899–1.132)
		p	0.291	0.001	0.365	0.788	0.878
Sim	ACEI	OR	0.989	0.962	0.981	0.946	0.941
		CI	(0.957–1.022)	(0.921–1.005)	(0.953–1.009)	(0.872–1.027)	(0.862–1.028)
		p	0.499	0.082	0.180	0.187	0.180
Pra	ACEI	OR	0.981	0.854	0.944	0.877	0.958
		CI	(0.927–1.038)	(0.787–0.926)	(0.897–0.992)	(0.738–1.043)	(0.784–1.169)
		p	0.504	<0.001	0.024	0.137	0.671
Rosu	ACEI	OR	0.832	0.858	0.848	0.672	0.902
		CI	(0.776–0.892)	(0.777–0.949)	(0.795–0.905)	(0.548–0.825)	(0.753–1.080)
		p	<0.001	0.003	<0.001	<0.001	0.261
Ator	ARB	OR	0.902	0.883	0.902	0.869	0.869
		CI	(0.862–0.945)	(0.819–0.953)	(0.863–0.942)	(0.757–0.999)	(0.744–1.014)
		p	<0.001	0.001	<0.001	0.048	0.074
Sim	ARB	OR	0.893	0.837	0.878	0.856	0.898
		CI	(0.860–0.928)	(0.785–0.893)	(0.846–0.911)	(0.763–0.960)	(0.802–1.005)
		p	<0.001	<0.001	<0.001	0.008	0.060
Pra	ARB	OR	0.824	0.703	0.797	0.770	0.877
		CI	(0.771–0.881)	(0.615–0.804)	(0.746–0.852)	(0.620–0.956)	(0.685–1.121)
		p	<0.001	<0.001	<0.001	0.018	0.294
Rosu	ARB	OR	0.833	0.784	0.798	0.902	0.842
		CI	(0.774–0.895)	(0.684–0.900)	(0.742–0.858)	(0.735–1.106)	(0.692–1.025)
		p	<0.001	0.001	<0.001	0.320	0.086
N			1,241,491	776,295	1,689,066	125,843	106,019

Open in a new tab

Logistic regression results for ADRD incidence in sample of 2009–2014 Medicare person-years with 90 possession days and 2 claims of both an AHT and a statin in both years t-1 and t-2. AHTs are antihypertensive (AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics), and statins are atorvastatin, pravastatin, rosuvastatin, and simvastatin. Sample restricted to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior ADRD diagnoses, and no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine. Controls are age, age squared, sex, education, income quartiles, statin use (t-1), years since hypertension and hyperlipidemic diagnoses, HCC comorbidity index, number of physician visits, and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial infarction, and stroke. Standard errors are clustered at the county level.

Table 2 also reports results of ORs separately by race/ethnicity. Among Hispanics, there is no combination of statins and RAS-acting AHTs compared to combinations of statins and non-RAS acting AHTs that is associated with lower risk of ADRD. Among blacks, the reduced risk associated with combined use of rosuvastatin and ACEI is large (OR = 0.672, CI: 0.548–0.825, p<0.001). Among blacks there is also reduced risk associated with combined use of simvastatin and ARBs (OR = 0.856, CI: 0.763–0.960, p = 0.008), atorvastatin and ARBs (OR = 0.869, CI: 0.757–0.999, p = 0.048), and pravastatin and ARBs (OR = 0.770, CI: 0.620–0.956, p = 0.018). Among whites, combined use of ARBs and any statin is associated with lower odds of ADRD relative to non-RAS acting AHTs and any statin.

Discussion

In this study, we examined the association between use of combined statin and RAS-acting AHT drug therapies and ADRD risk, compared to risk associated with combined statin and non-RAS acting AHT therapy. RAS-acting AHTs were disaggregated into ACEIs and ARBs, and statins were disaggregated by molecule (atorvastatin, pravastatin, rosuvastatin, and simvastatin). No previous study has investigated the association of different combinations of these frequently used drugs and ADRD risk in a large and broadly representative sample of older Americans and across sex and racial and ethnic subpopulations. Among elderly adults, who were using drugs to treat hypertension and dyslipidemia we found substantial variation in ADRD risk reductions across different combinations of statins and AHTs, and across different populations. The greatest reductions, as compared to individuals using statins and non-RAS acting AHTs, were for individuals using ARBs in combination with pravastatin or rosuvastatin. These results were robust to varying definitions of drug use (90, 180, and 270 days) (S2 and S3 Tables). This finding held in some subpopulations: women, men, whites, and blacks. Our detection of significant reduction in ADRD risk for black men using specific combinations of statins and RAS-acting AHTs is important, as this group was not previously found to benefit from either statin therapy or RAS-acting AHT therapy [16, 44].

The magnitudes of estimated risk reductions were meaningful; for example, using ARBs combined with pravastatin was associated with 21% lower odds of ADRD, as compared to individuals using other statins and non-RAS acting AHTs in combination (OR = 0.794, CI: 0.748–0.843, p<0.001). As for users of ACEIs, the other RAS-acting AHT, only in combination with rosuvastatin was there an associated reduction in risk of ADRD among older American populations of women, men, whites, and blacks as compared to those same populations using statins and non-RAS acting AHTs. This association was robust to varying definitions of use (90, 180, and 270 days) (S2 and S3 Tables). While our results show greater protection for combinations that involve rosuvastatin or pravastatin, these drugs are not as frequently used as atorvastatin and simvastatin. In 2007, 2.9% of Medicare beneficiaries with fee-for-service (FFS) and Part D used pravastatin, and 3.3% used rosuvastatin, compared to 15.6% for atorvastatin, and 18.1% for simvastatin (Fig 2). Use of rosuvastatin and pravastatin has grown over time to 8.9% and 5.8% in 2014 for pravastatin and rosuvastatin, respectively (Fig 2). Rosuvastatin has shown strong growth in market share since its branded version, Crestor, lost patent protection in the United States in 2016 [48]. In 2017, rosuvastatin was the sixth fastest growing mail and retail prescription in the U.S., with an additional 6.8 million 90-day equivalent prescriptions [49]. The pharmacokinetics and pharmacodynamics of rosuvastatin are distinct from other statins, and may be a contributing factor to the differences we found [50, 51]. Rosuvastatin appears to have preferential benefit over other statins with respect to favorable low-density lipoprotein (LDL) cholesterol-lowering efficacy, as well as lower likelihood of side effects due t low extra-hepatic penetration and interference with cytochrome P450 related drug interactions [51]. In the ARIES trial, rosuvastatin improved the overall lipid profile of hypercholesterolemic African-Americans better than the milligram-equivalent doses of atorvastatin [52]. As the use of these molecules increases, additional benefits may be conferred for older adults of diverse backgrounds.

Fig 2 — Sample is Medicare beneficiaries with fee-for-service and Part D coverage in the year of the horizontal axis. Use of a drug is defined as 90 days and 2 claims. Abbreviations: ACEI (angiotensin converting enzyme inhibitors), ARB (angiotensin-II receptor blockers), RAS (renin-angiotensin system), non-RAS AHTs (beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics).

In this study we cannot test what mechanisms are driving the differential associations that were observed between the four statins investigated, all of which work to reduce low-density lipoprotein (LDL) cholesterol levels, and combinations of ARBs or ACEIs. A potential mechanism, and one that may explain some of the ethnic differences observed, are differences in drug metabolism and transport. Rosuvastatin, for example, is metabolized by CYP2C9 and CYP2C19 cytochrome P-450 enzymes. These CYP enzymes could be related to differential associations with ADRD in two ways. First, if there are pharmacokinetic interactions between certain statins and certain AHTs, the metabolism of one or both drugs could be altered in a way that confers differential benefit regarding ADRD. CYP2C9, for example, metabolizes Rosuvastatin, and is a substrate for several ARBs (e.g., losartan and irbesartan), potentially leading to interactions [53]. Second, statins and/or AHTs may affect the activity of CYP enzymes that have a direct impact on ADRD risk factors. For example, some genetic variants in CYP2C19 confer protection against amyloid-beta burden in persons with AD [54]. Additionally, CYP2C9 is encoded for by a gene previously linked to familial AD [55].

Atorvastatin and simvastatin, while failing to show a protective association against ADRD when combined with ACEIs (compared to other combinations of statins and AHTs), were observed to be protective when combined with ARBs. This might be due to an interaction effect with ARBs on metabolism and transport, similar to what was described for rosuvastatin and ARBs. While they are different in their duration of action (atorvastatin is a long acting statin and simvastatin is a short acting one), both are metabolized by CYP3A4 that has, as with CYP2C9, been shown to have common ARBs as a substrate [53]. The observed variability of benefit may therefore be highlighting underlying differences in some of the drug metabolic processes of these statins. Additionally, these enzymes are encoded by several genes, many of which (e.g., CYP3A4, CYP2D6, CYP2C19) are polymorphic with variable prevalence of different alleles that normally affect metabolizing phenotype in different race/ethnicities [56, 57]; while there is some evidence supporting CYP3A4 variant statin metabolism [56], the clinical significance of these in relation to the drugs studied is unclear. Furthermore, some of the observed differences in protection across race/ethnicity could be caused by differences in the endogenous sodium and renin levels in the peripheral RAS, as was discussed in our earlier work on this subject [44].

The strong protective association of pravastatin is difficult to explain. It is metabolized by glucuronidation rather than cytochrome P450 metabolism [58], and while metabolic changes are often reported in AD [59], it is not clear whether there are any disease-related differences in glucuronidation in AD that might influence how pravastatin is metabolized.

There is some evidence that a net effect of reducing the formation of very low density lipoproteins (VLDLs), precursors of LDLs, can increase levels of LDL receptors [60]. One receptor that might be similarly affected is LRP1, a receptor of VLDLs but also a major factor in receptor-mediated clearance of amyloid-beta in AD [61]. Whether this would be a peripheral or central effect is not determined.

Dyslipidemia and hypertension are both independent risk factors of ADRD, and control of both via lifestyle and medications has been associated with lower incidence and prevalence of ADRD. Recent results from the SPRINT MIND trial found that aggressive blood pressure control (120 mmHg, vs less than 140 mm Hg) was associated with smaller increases in white matter lesion volume [62]. While the present study was not able to address variation in clinical values of blood pressure, we found that hypertension treatment with RAS-acting AHTs plus certain statins may confer ADRD related brain benefits beyond peripheral control of vascular disease.

In addition to controlling blood pressure, RAS medications and to a greater extent ARBs, improve endothelial function, insulin response, and decrease inflammation. Combined statin-based and RAS inhibitor therapies demonstrate additive/synergistic beneficial effects on endothelial dysfunction, insulin resistance, and other metabolic parameters in addition to lowering both cholesterol levels and blood pressure. Mechanistically, the combination of reduced inflammation, improved blood brain barrier integrity, and improved metabolic health all provide a reasonable rationale for reduced risk of ADRD in persons using combined statins and ARBs.

This study has limitations. First, there is a possibility of confounding by indication, wherein individuals who may be differentially predisposed toward ADRD risk are sorted into certain combinations of statins and AHTs. Our study adjusted for many sources of possible bias, but the possibility of unmeasured bias remains. Second, use of AHTs and statins could be imprecisely measured. We analyze robustness of results to different (higher) thresholds of days of use. Drug use in the years prior to Medicare Part D (pre-2006) could confound analyses, if it varies across our comparison groups (different combinations of drugs). Accordingly, we adjust models for years since hypertension and hyperlipidemia diagnoses. Another source of measurement error may be due to individuals switching between molecules or classes within a year, but this would bias results toward zero. Third, timing of ADRD diagnoses in claims data may not represent the true onset of the condition. However, our sample is all users of statins and AHTs and there is no evidence to suggest that diagnostic practices would vary by different combination of statins and AHTs, and therefore imprecise diagnoses would not bias the results. Fourth, the sample is restricted to Medicare beneficiaries enrolled in FFS and Part D (approximately two thirds of Medicare beneficiaries), and thus excludes those in Medicare Advantage or in FFS and not enrolled in Part D, who tend to be slightly healthier on average [45]. Finally, with these data, we cannot test the hypotheses of the various potential mechanisms that may explain the variation by molecule and drug class, and by race and ethnicity that we observed.

Conclusion

Nearly a quarter of the elderly in the U.S. use both statins and AHTs to treat or prevent dyslipidemia, hypertension, and cardiovascular disease. We found that RAS-acting ARBs combined with pravastatin or rosuvastatin reduced ADRD risk reductions more than statins combined with non-RAS acting AHTs, which may reflect or be dependent on underlying gene polymorphism-associated differences in drug metabolic processes. If these findings are replicated, specific combinations of statins and antihypertensives might be recommended in the interest of reducing ADRD risk. Fewer older adults use pravastatin and rosuvastatin than other simvastatin and atorvastatin. Over time, use of pravastatin and rosuvastatin and ARBs have increased, potentially conferring population benefits of reduced dementia risk.

Supporting information

S1 Appendix. Summary of ICD-9 codes used to define various diagnoses and symptoms.

(DOCX)

Click here for additional data file.^{(11.5KB, docx)}

S1 Table. Adjusted odds ratios of AD incidence associated with use of statin-AHT combinations, relative to users of other statin-AHT combinations.

Logistic regression results for AD incidence in sample of 2009–2014 Medicare person-years with 90 possession days and 2 claims of both an AHT and a statin in both years t-1 and t-2. AHTs are antihypertensive (AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics), and statins are atorvastatin, pravastatin, rosuvastatin, and simvastatin. Sample restricted to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior AD diagnoses, and no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine. Controls are age, age squared, sex, education, income quartiles, statin use (t-1), years since hypertension and hyperlipidemic diagnoses, HCC comorbidity index, number of physician visits, and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial infarction, and stroke. Standard errors are clustered at the county level.

(DOCX)

Click here for additional data file.^{(15.4KB, docx)}

S2 Table. Adjusted odds ratios of ADRD incidence associated with use of statin-AHT combinations, relative to users of other statin-AHT combinations, with use defined as 180 days and 2 claims.

Logistic regression results for ADRD incidence in sample of 2009–2014 Medicare person-years with 180 possession days and 2 claims of both an AHT and a statin in both years t-1 and t-2. AHTs are antihypertensive (AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics), and statins are atorvastatin, pravastatin, rosuvastatin, and simvastatin. Sample restricted to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior ADRD diagnoses, and no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine. Controls are age, age squared, sex, education, income quartiles, statin use (t-1), years since hypertension and hyperlipidemic diagnoses, HCC comorbidity index, number of physician visits, and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial infarction, and stroke. Standard errors are clustered at the county level.

(DOCX)

Click here for additional data file.^{(15.4KB, docx)}

S3 Table. Adjusted odds ratios of ADRD incidence associated with use of statin-AHT combinations, relative to users of other statin-AHT combinations, with use defined as 270 days and 2 claims.

Logistic regression results for ADRD incidence in sample of 2009–2014 Medicare person-years with 270 possession days and 2 claims of both an AHT and a statin in both years t-1 and t-2. AHTs are antihypertensive (AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics), and statins are atorvastatin, pravastatin, rosuvastatin, and simvastatin. Sample restricted to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior ADRD diagnoses, and no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine. Controls are age, age squared, sex, education, income quartiles, statin use (t-1), years since hypertension and hyperlipidemic diagnoses, HCC comorbidity index, number of physician visits, and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial infarction, and stroke. Standard errors are clustered at the county level.

(DOCX)

Click here for additional data file.^{(15.6KB, docx)}

Data Availability

The primary data source for the project is CMS Medicare claims data. The CMS data used in this project cannot be shared with other researchers under the terms of our Data Use Agreement (DUA). A researcher can request access to the same data and obtain their own DUA through the CMS Data Request Center (https://www.resdac.org/cms-data/request/cms-data-request-center). The researcher should request Research Identifiable Files. See https://www.resdac.org/cms-data/request/research-identifiable-files. Assistance for accessing and using these data is made available by the Research Data Assistance Center (ResDAC). ResDAC is a consortium of faculty and staff from the University of Minnesota, Boston University, Dartmouth Medical School, and the Morehouse School of Medicine. ResDAC provides free assistance to academic and non-profit researchers interested in using Medicare, Medicaid, SCHIP, and Medicare Current Beneficiary Survey (MCBS) data for research. We will make available the code that is used to generate our analytic data files and conduct the analyses, and anyone will be able to download the code from the repository hosted at https://healthpolicy.box.com/v/Barthold-2019-Statins-AHT-Code. Also included will be a “readme” file that explains how a researcher can get access to the data and a description of the files that will guide a researcher through use of the code.

Funding Statement

This research was supported by National Institutes of Health (NIH), awards R01AG055401, P30AG043073, K01AG042498, P01AG026572, R01HL126804, and R01HL130462, and the University of Southern California Zumberge Research Fund, 1R34AG049652. Douglas Barthold was supported through the Schaeffer-Amgen Fellowship Program funded by Amgen. Patrick Kehoe was supported by a Fellowship from the Sigmund Gestetner Foundation, and NIHR-EME, Alzheimer's Society, Alzheimer's Research UK, BRACE, the Medical Research Council, and the British Heart Foundation. Sponsors’ role: The sponsors had no role in the design, methods, analysis, interpretation, or preparation of the paper.

References

1.Zissimopoulos J.M., et al. The impact of changes in population health and mortality on future prevalence of Alzheimer’s disease and other dementias in the United States. The Journals of Gerontology: Series B, 2018. 73(suppl_1): p. S38–S47. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Chen C. and Zissimopoulos J.M., Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2018. 4: p. 510–520. [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Lourida I., et al. Association of Lifestyle and Genetic Risk With Incidence of Dementia. JAMA, 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
4.World Health Organization, Risk reduction of cognitive decline and dementia: WHO guidelines, in Risk reduction of cognitive decline and dementia: WHO guidelines; 2019. 10.1177/1471301217699675 [DOI] [PubMed] [Google Scholar]
5.Livingston G., et al. Dementia prevention, intervention, and care. The Lancet, 2017. 390(10113): p. 2673–2734. [DOI] [PubMed] [Google Scholar]
6.Zissimopoulos J., Crimmins E. and St Clair P., The Value of Delaying Alzheimer’s Disease Onset. Forum for Health Economics and Policy, 2015. 18(1): p. 25–39. [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Chong P.H., Seeger J.D. and Franklin C., Clinically relevant differences between the statins: implications for therapeutic selection. The American Journal of Medicine, 2001. 111(5): p. 390–400. 10.1016/s0002-9343(01)00870-1 [DOI] [PubMed] [Google Scholar]
8.Kandiah N. and Feldman H.H., Therapeutic potential of statins in Alzheimer's disease. Journal of the Neurological Sciences, 2009. 283(1): p. 230–234. [DOI] [PubMed] [Google Scholar]
9.Reed B., et al. Low HDL and High LDL Serum Cholesterol Are Associated With Cerebral Amyloidosis. JAMA Neurology, 2014. 71(2): p. 195 10.1001/jamaneurol.2013.5390 [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Lesser G., et al. Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles. Current Alzheimer Research, 2011. 8(3): p. 303 10.2174/156720511795563755 [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Petanceska S.S., et al. Statin therapy for Alzheimer’s disease. Journal of Molecular Neuroscience, 2002. 19(1–2): p. 155–161. 10.1007/s12031-002-0026-2 [DOI] [PubMed] [Google Scholar]
12.Refolo L.M., et al. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiology of Disease, 2001. 8(5): p. 890–899. 10.1006/nbdi.2001.0422 [DOI] [PubMed] [Google Scholar]
13.Richardson K., et al. Statins and cognitive function: a systematic review. Annals of Internal Medicine, 2013. 159(10): p. 688–697. 10.7326/0003-4819-159-10-201311190-00007 [DOI] [PubMed] [Google Scholar]
14.Shepardson N.E., Shankar G.M. and Selkoe D.J., Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Archives of Neurology, 2011. 68(11): p. 1385–1392. 10.1001/archneurol.2011.242 [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Schultz B.G., Patten D.K. and Berlau D.J., The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Translational Neurodegeneration, 2018. 7(1): p. 5. [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Zissimopoulos J.M., et al. Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease. JAMA Neurology, 2017. 74(2): p. 225–232. 10.1001/jamaneurol.2016.3783 [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Redelmeier D.A., Manzoor F. and Thiruchelvam D., Association Between Statin Use and Risk of Dementia After a Concussion. JAMA Neurology, 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Haag M.D., et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. Journal of Neurology, Neurosurgery & Psychiatry, 2009. 80(1): p. 13–17. [DOI] [PubMed] [Google Scholar]
19.Jick H., et al. Statins and the risk of dementia. The Lancet, 2000. 356(9242): p. 1627–1631. [DOI] [PubMed] [Google Scholar]
20.Li G., et al. Age‐Varying Association Between Statin Use and Incident Alzheimer's Disease. Journal of the American Geriatrics Society, 2010. 58(7): p. 1311–1317. 10.1111/j.1532-5415.2010.02906.x [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Lin F.-C., et al. Early Statin Use and the Progression of Alzheimer Disease: A Total Population-Based Case-Control Study. Medicine, 2015. 94(47): p. e2143 10.1097/MD.0000000000002143 [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Wolozin B., et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Medicine, 2007. 5(1): p. 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Geifman N., et al. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. Alzheimer's Research & Therapy, 2017. 9(1): p. 10. [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Geifman N., et al. Data-driven identification of endophenotypes of Alzheimer’s disease progression: implications for clinical trials and therapeutic interventions. Alzheimer's Research & Therapy, 2018. 10(1): p. 4. [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Li G., et al. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults. Neurology, 2017. 89(12): p. 1251–1255. 10.1212/WNL.0000000000004392 [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Li G., et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology, 2007. 69(9): p. 878–885. 10.1212/01.wnl.0000277657.95487.1c [DOI] [PubMed] [Google Scholar]
27.Rouch L., et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs, 2015. 29(2): p. 113–130. 10.1007/s40263-015-0230-6 [DOI] [PubMed] [Google Scholar]
28.Marpillat N.L., et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. Journal of Hypertension, 2013. 31(6): p. 1073–1082. 10.1097/HJH.0b013e3283603f53 [DOI] [PubMed] [Google Scholar]
29.Peters R., et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. The Lancet Neurology, 2008. 7(8): p. 683–689. 10.1016/S1474-4422(08)70143-1 [DOI] [PubMed] [Google Scholar]
30.van Charante E.P.M., et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. The Lancet, 2016. 388(10046): p. 797–805. [DOI] [PubMed] [Google Scholar]
31.Miners J., et al. Angiotensin‐converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE‐1 to cerebral amyloid angiopathy. Neuropathology and Applied Neurobiology, 2008. 34(2): p. 181–193. 10.1111/j.1365-2990.2007.00885.x [DOI] [PubMed] [Google Scholar]
32.Miners S., et al. Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. American Journal of Translational Research, 2009. 1(2): p. 163 [PMC free article] [PubMed] [Google Scholar]
33.Miners J.S., et al. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. Journal of Neuropathology & Experimental Neurology, 2011. 70(11): p. 944–959. [DOI] [PubMed] [Google Scholar]
34.Kehoe P.G., et al. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology. Alzheimer's Research & Therapy, 2016. 8(1): p. 50. [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Kehoe P.G., The coming of age of the angiotensin hypothesis in Alzheimer's disease–progress towards disease prevention and treatment? Journal of Alzheimer's Disease, 2018. 62(3). [DOI] [PMC free article] [PubMed] [Google Scholar]
36.Kehoe P.G. and Wilcock G.K., Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer's disease? The Lancet Neurology, 2007. 6(4): p. 373–378. 10.1016/S1474-4422(07)70077-7 [DOI] [PubMed] [Google Scholar]
37.Kehoe P.G., Miners S. and Love S., Angiotensins in Alzheimer's disease–friend or foe? Trends in Neurosciences, 2009. 32(12): p. 619–628. 10.1016/j.tins.2009.07.006 [DOI] [PubMed] [Google Scholar]
38.Wharton W., et al. Neurofibrillary Tangles and Conversion to Mild Cognitive Impairment with Certain Antihypertensives. Journal of Alzheimer's Disease, 2019(Preprint): p. 1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Wharton W., et al. Modulation of Renin‐Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease. Journal of the American Geriatrics Society, 2015. 63(9): p. 1749–1756. 10.1111/jgs.13627 [DOI] [PMC free article] [PubMed] [Google Scholar]
40.Hajjar I., et al. Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Archives of Neurology, 2012. 69(12): p. 1632–1638. 10.1001/archneurol.2012.1010 [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Hajjar I., et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society, 2013. 61(2): p. 194–201. 10.1111/jgs.12100 [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Li N.-C., et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ, 2010. 340: p. b5465 10.1136/bmj.b5465 [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Evans C.E., et al. Exploring ACE-2 as a novel therapeutic target for Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018. 14(7): p. P1659. [Google Scholar]
44.Barthold D., et al. The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity. PLOS ONE, 2018. 13(11). [DOI] [PMC free article] [PubMed] [Google Scholar]
45.Neuman P. and Jacobson G., Medicare Advantage Checkup. The New England Journal of Medicine, 2018. 379(22): p. 2163–2172. 10.1056/NEJMhpr1804089 [DOI] [PubMed] [Google Scholar]
46.Li P., Kim M.M. and Doshi J.A., Comparison of the performance of the CMS Hierarchical Condition Category (CMS-HCC) risk adjuster with the Charlson and Elixhauser comorbidity measures in predicting mortality. BMC Health Services Research, 2010. 10(1): p. 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
47.Bonito A., et al. Creation of new race-ethnicity codes and socioeconomic status (SES) indicators for Medicare beneficiaries. 2008, Agency for Healthcare Research and Quality, and Center for Medicare and Medicaid Services: Rockville, MD. [Google Scholar]
48.Aitken M., et al. Medicines use and spending in the US: a review of 2016 and outlook to 2021. Parsippany: IMS Institute for Healthcare Informatics, 2016. [Google Scholar]
49.Long D. Global Generic and Biosimilars Trends and Insights in Association for Accesible Medicines. 2018. IQVIA. [Google Scholar]
50.Luvai A., et al. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clinical Medicine Insights: Cardiology, 2012. 6: p. CMC. S4324. [DOI] [PMC free article] [PubMed] [Google Scholar]
51.White C.M., A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. The Journal of Clinical Pharmacology, 2002. 42(9): p. 963–970. [PubMed] [Google Scholar]
52.Ferdinand K.C., et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. The American Journal of Cardiology, 2006. 97(2): p. 229–235. 10.1016/j.amjcard.2005.08.026 [DOI] [PubMed] [Google Scholar]
53.Flockhart, D.A. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine 2007 September 1, 2019]; Available from: https://drug-interactions.medicine.iu.edu
54.Benedet A.L., et al. CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem. Neurology Genetics, 2018. 4(1): p. e216 10.1212/NXG.0000000000000216 [DOI] [PMC free article] [PubMed] [Google Scholar]
55.ALZGENE. Chromosome 10: Location of Published AD Candidate Genes. 2019 September 1, 2019]; Available from: http://www.alzgene.org/chromo.asp?c=10
56.Wang D., et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. The Pharmacogenomics Journal, 2011. 11(4): p. 274 10.1038/tpj.2010.28 [DOI] [PMC free article] [PubMed] [Google Scholar]
57.McGraw J. and Waller D., Cytochrome P450 variations in different ethnic populations. Expert opinion on drug metabolism & toxicology, 2012. 8(3): p. 371–382. [DOI] [PubMed] [Google Scholar]
58.Jacobsen W., et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metabolism and Disposition, 1999. 27(2): p. 173–179. [PubMed] [Google Scholar]
59.Xu J., et al. Graded perturbations of metabolism in multiple regions of human brain in Alzheimer's disease: Snapshot of a pervasive metabolic disorder. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2016. 1862(6): p. 1084–1092. [DOI] [PMC free article] [PubMed] [Google Scholar]
60.Vaughan C.J. and Gotto A.M. Jr, Update on statins: 2003. Circulation, 2004. 110(7): p. 886–892. 10.1161/01.CIR.0000139312.10076.BA [DOI] [PubMed] [Google Scholar]
61.Deane, R., et al., Clearance of amyloid-β peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 2009. 8(1): p. 16–30. [DOI] [PMC free article] [PubMed]
62.Nasrallah I.M., et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA, 2019. 322(6): p. 524–534. 10.1001/jama.2019.10551 [DOI] [PMC free article] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0229541.r001

Decision Letter 0

Tarek K Rajji

2 Dec 2019

PONE-D-19-25705

Association of combination statin and antihypertensive therapy with reduced Alzheimer’s disease and related dementia risk

PLOS ONE

Dear Barthold,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jan 16 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Tarek K Rajji

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

1. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for the opportunity to review this manuscript. Overall, I was happy with the conduct of the study, the large sample size and robust analysis. The findings have high clinical interest as the problem of Alzheimer’s/related dementias is very prevalent, as is co-morbidity of hypertension and hypercholesterolemia in older people. Given that statins and antihypertensive drugs are widely used, the finding that certain commonly used combinations might offer greater protection against Alzheimer’s/related dementias than others is of great relevance.

There is room for improvement in this manuscript in two areas.

A) Issues in the descriptions relating to the clinical pharmacology of the drugs studied

1) Line 295 – ‘The pharmacology and pharmacokinetics of rosuvastatin are distinct’. First, this is strangely worded as pharmacokinetics are an aspect of pharmacology – this would be better phrased as ‘the pharmacokinetics and pharmacodynamics …’. I would like to see this statement explained further – in what way is rosuvastatin pharmacologically different from the others? Does this extend beyond the pharmacokinetic issues discussed in the following lines to some unique pharmacodynamic/mechanistic property ? I would think that explaining these differences are central to the argument that there is a pharmacological justification underlying the findings.

2) Line 304. The authors talk of the relative potency of the four statins differing from the observed relative benefits in protection against Alzheimer’s – which might mean the protective effect vs Alzheimer’s is mediated by a different mechanism from the LDL-lowering effect. But is potency the key measure here ? Is it not the product of potency and typical dosage – i.e. if drug A is 10 times as potent as drug B, but drug B is typically used at 20 times the dose of drug A, then we would expect drug B, not drug A to offer the most protection (assuming the anti-dementia effect is medicated through the same initial mechanism as the lipid lowering effect)? Presumably also, the statins all have similar efficacy in lipid lowering when used at their standard doses (which therefore offset the differences in potency) or else a literature would have emerged on certain molecules being associated with greater lipid-lowering efficacy than others. So essentially I am not convinced regarding lines the argument from line 304-306.

3) Line 306-313 - The points relating to the CYP metabolizing enzymes are difficult to follow. There appear to be two points which need to be considered separately – i.e. a) there might be CYP-based pharmacokinetic interactions between certain statins and certain antihypertensive agents resulting in higher concentration/dose ratio of one or both drugs which might have an impact on the protective effect against ADRD and b) the impact of statins or antihypertensive drugs on activity of certain CYP enzymes might have a direct impact on risk of ADRD if the presence of the CYP enzyme is itself a risk factor or protective factor for ADRD. Point (a) is weakened by the fact that, according to Flockhart’s table, the statins and antihypertensives are substrates of certain CYP enzymes but are not strong inhibitors so there may often be sufficient metabolizing capacity that the co-prescription of two drugs metabolized by the same CYP may have no impact on their concentrations. As regards point (b) - the genetic variants in CYP expression (such as in CYP2C9 and CYP2C19 which metabolize rosuvastatin) and their ramifications for protection against dementia would already be inherent to the individual whether or not they ever took rosuvastatin (or any other substrate medication), and would only come in to play for the rosuvastatin if perhaps an individual was genetically already a low capacity metabolizer, or co-prescribed a 2C9/2C19 inhibitor, and the presence of rosuvastatin and the appropriate ARB could then inhibit what limited CYP2C9/CYP2C19 activity remained. All in all this is speculative and in my opinion the putative pharmacokinetic mechanisms have been given undue prominence (the CYP suggestions account for over half of the discussion of mechanisms). I would advise organizing this section more logically to cover the (a) and (b) points. The authors may wish to add a small table (or even a bulleted list) derived from Flockhart or similar sources, which allows the user to see which CYPs are involved in the metabolism of the four statins, and the main ARBs and ACE inhibitors and non-ARB antihypertensives, this would allow the potential interactions to be appraised quickly and easily and would demystify this section.

4) Line 324 – I have some reservations with the statement that CYP3A4 is a ‘highly polymorphic enzyme’. It would be reasonable to say ‘polymorphic’. Evidence that this is of functional importance relative to other CYPs is limited. A review by Mizutani T(2003) Drug Metabolism reviews ‘PM Frequencies of Major CYPs in Asians and Caucasians’ pp99-106, stated a Poor Metabolizer frequency for CYP3A4 of 0% in Caucasians (table 2) and 1% in East Asians (table 1), the corresponding figures for CYP2D6 being 7% for in Caucasians and 0.8% in East Asians – while for CYP2C19 19% of East Asians are reported as being poor metabolizers. Looking at the paper the authors referenced (McGraw & Waller, ref 54) it appears that this paper lumps together CYP3A4 with CYP3A5 and describes more heterogeneity with CYP3A5 than CYP3A4. For CYP3A4 it mentions that a 3A4*1B allele is fairly common in African Americans and less so in Caucasians but also states that ‘the clinical impact of this polymorphism has not yet been identified’. There is however some potentially relevant evidence cited in this paper about a CYP3A4*22 allele (presumably associated with an extensive metabolizer phenotype) having impact on simvastatin metabolism. I think the case would be stronger here if you were to also cite and describe the original research relating to this allele (ref 63 Wang , Guo , Wrighton et al who refer to it as a ‘functional SNP located in intron 6’) as this paper provides direct evidence of a CYP3A4-related variant which impacts on statin metabolism.

B) Issues in Sample Description and justification of representativeness

Second, there are some shortcomings in the sample descriptions. In particular – and I think this is of particular relevance to readers not closely familiar with the healthcare system in the USA - the descriptions of the Medicare system (lines 153-158) are inadequate. The general reader needs to know how what is ‘Medicare’ and how is it funded – is this government funded care as is commonly found in Canada and the European Union, is it a wholly privately funded insurance system or some combination of the two? What proportion of US residents/citizens are covered by or registered for Medicare? Was the sample drawn from 20% of Medicare beneficiaries in one specific part of the USA or from 20% of the entire US population registered with correct form of Medicare, aged over 67 and meeting the remaining criteria?

Crucially, there is no discussion of how representative the sample of individuals registered to receive Medicare included in the present study is of the general population in the USA. E.g. Are economically disadvantaged people and ethnic minorities under-represented or over-represented in the population registered to receive Medicare ? The representativeness of the sample must be discussed and if necessary listed as a limitation. I note that in line 271 the sample is described as ‘broadly representative’ but the authors have not given sufficient information to justify this assumption. Further the authors go on (in the discussion) to give further details about the Medicare-based sample using including concepts such as ‘FFS’ (‘fee for service’) and ‘part D’ which is described earlier (line 155) as “part D claims include key elements related to prescription drug events’ - I’m sorry but this is impenetrable to me and will similarly be impenetrable to some readers – these differing gradations of the Medicare system need to be explained in more generic terms for readers unfamiliar with your system. What (line 366) is the ramification for the respresentativeness of the sample of excluding people in FFS without part D or in Medicare advantage? These concepts must be defined in the methods section or it is impossible for the reader to judge.

C) Further Question

Do the authors consider that there is a possibility of ‘confounding by indication’ – i.e. certain patient characteristics encouraging prescribers to prefer or avoid certain drugs in patients with attributes which might themselves be risk factors for dementia. One example might be using beta blockers preferentially as an antihypertensive drug of choice in patients exhibiting longstanding anxiety which could, through its associations both with depression and cardiovascular disease be associated with development of dementia. I am not suggesting that this is a sufficiently important issue that it demands that some mitigating methodology such as propensity-score matching should have been used, but I think the possibility of this occurring should be mentioned.

D) Minor points

1) In the Abstract – ‘FINDINGS’ section, the phrase “Pravastatin and rosuvastatin combined… “ is ambiguous, would be better phrased as “Pravastatin OR rosuvastatin combined…”

2) In the Abstract – ‘METHODS’ section – the last sentence is a little confusing and would be improved by changing the final ‘and’ to “vs.”

3) In the Abstract – ‘CONCLUSION’ section – I suggest changing ‘… is less common than other statins’ to is ‘is less common than use of simvastatin or atorvastatin. This is because other statins exist which are not mentioned in this manuscript, e.g. fluvastatin and lovastatin. This also applies in line 374 (conclusion).

4) In the Introduction, lines 121 – 123. I would suggest providing more information on the observational studies rather than merely referencing that they exist. Being picky, it is actually incorrect to say that they are all ‘more recent’ than the RCTs. But I believe the reader would be better served if there could be some greater detail and critique about these studies (at least those that the authors view as the most important), as understanding what they have found is essential to the context of the present study.

5) Line 135 – in defining ‘other AHT drug classes’ only calcium channel blockers, beta blockers and thiazides are mentioned – note the bracket is an ‘i.e.’ (suggesting there should be a complete list) and not an ‘e.g.’. The obvious missed class is loop diuretics which as I understand are still commonly used and were included in this study. What also of other less common AHT classes – alpha blockers, mixed alpha/beta blockers (e.g. carvidelol), vasodilators, centrally acting alpha-2 agonists? Can the authors add a line (around line 175) in the methods to justify excluding these less commonly used drug classes?

6) Line 293 – can the authors clarify if the loss of patent protection for Crestor/Rosuvastatin described in 2016 was specific to the United States?

7) Line 320 – I wonder if ‘CYP2CP’ is a typo – the referenced Flockhart table (ref 53) lists CYP2C9 and CYP2C19 as well as the less familiar CYP2C8, presumably this should be CYP2C9? Alternatively perhaps this is not a typo and the authors are using ‘CYP2CP’ as an umbrella term to refer to all the CYP2C enzymes - this would however be an unusual usage. Either way this needs clarification.

8) Conclusion – I would suggest adding a sentence to state that these findings, if replicated, suggest a possibility that certain antihypertensive-statin combinations might be recommended preferentially to older adults in the interest of reducing risk of ADRD.

Reviewer #2: This is an exciting paper using large databases of Medicare beneficiaries to examine the combination of statin and antihypertensive therapy (AHT) and related dementia risk. This is an important topic, because a common recommendation for patients to prevent dementia is to take statins and AHTs, although real-world data with large enough sample size to assess the effects of individual statin/AHT combos is limited. I only have some major and minor comments:

1. Is the overall combo of statin (any) + AHT (any) has a beneficial association with dementia, relative to a non-AHT, non-statin comparator? This could be reported in the abstract - since a clinician reading this paper, may get a "blanket message" that any combo is good - whereas perhaps only certain combinations are helpful

2. It's not clear in the abstract what your primary question is - whether (or not) any combo of statin(any)/AHT(any) will be associated with improved outcome (this is what seems to be); and if not - whether you are particularly interested in certain drug combinations (and which of those is your primary question)

3. Even though this is a large set - it's not clear whether the sample size was necessarily large enough to test each of the combinations separately - If this is the case, it should be reported in the limitations section.

4. Study Design - This is not clear - is this a cohort study (which it seems to be) or is it a nested case control design or other design? Also it is not clear how long the maximum follow up (seems to be 5 years, but can be made more explicit)? Did you only include people with 2 years of AHT/statin use? What happened to people with shorter durations of use - were they excluded completely (ideal) or put in the reference group?

5. Another important limitation of the study is that it used a prevalent user (of AHT/statin) cohort - as opposed to a new-user design (previously unexposed to AHT/statin), which weakens causality. This should be mentioned in the limitations

Minor comment:

6. Sometimes ORs are reported in three digits - OR=0.942 - the industry standard is sometimes 0.94 in such cases. The journal could let you know if they have a preference for how to report such statistcis.

7. Ideally a statistician reviewer from the journal should also double-check this paper.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Mar 4;15(3):e0229541. doi: 10.1371/journal.pone.0229541.r002

Author response to Decision Letter 0

16 Jan 2020

Our responses to reviewers are in the response to reviewers file.

Attachment

Submitted filename: Response to reviewers - Statins+AHT - 20 01 16.docx

Click here for additional data file.^{(28KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0229541.r003

Decision Letter 1

Tarek K Rajji

10 Feb 2020

Association of combination statin and antihypertensive therapy with reduced Alzheimer’s disease and related dementia risk

PONE-D-19-25705R1

Dear Dr. Barthold,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Tarek K Rajji

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Reviewer #1: Thank you. I have gone through the authors’ changes and am happy with them – relating in particular to the descriptions of clinical pharmacology of the drugs studied and to the sample description/justification of representativeness (including the much improved descriptions of the Medicare-based enrollment). I have no further major comments.

Minor points

1) Please note there is a minor typo in line 315: ‘t’ should be ‘to’.

2) Line 388-389 Re: ‘Our study adjusted for many sources of possible bias that may lead to differential use of certain combinations of statins and AHTs, but the possibility of unmeasured bias remains.’ – I would invite the authors to consider whether strictly speaking this statement is referring to ‘confounding’ rather than ‘bias’.

Reviewer #2: The authors appear to have appropriately responded to my questions regarding the manuscript. I have no further recommendations.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Simon J C Davies

Reviewer #2: No

PLoS One. doi: 10.1371/journal.pone.0229541.r004

Acceptance letter

Tarek K Rajji

18 Feb 2020

PONE-D-19-25705R1

Association of combination statin and antihypertensive therapy with reduced Alzheimer’s disease and related dementia risk

Dear Dr. Barthold:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Tarek K Rajji

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Appendix. Summary of ICD-9 codes used to define various diagnoses and symptoms.

(DOCX)

Click here for additional data file.^{(11.5KB, docx)}

S1 Table. Adjusted odds ratios of AD incidence associated with use of statin-AHT combinations, relative to users of other statin-AHT combinations.

(DOCX)

Click here for additional data file.^{(15.4KB, docx)}

S2 Table. Adjusted odds ratios of ADRD incidence associated with use of statin-AHT combinations, relative to users of other statin-AHT combinations, with use defined as 180 days and 2 claims.

(DOCX)

Click here for additional data file.^{(15.4KB, docx)}

S3 Table. Adjusted odds ratios of ADRD incidence associated with use of statin-AHT combinations, relative to users of other statin-AHT combinations, with use defined as 270 days and 2 claims.

(DOCX)

Click here for additional data file.^{(15.6KB, docx)}

Attachment

Submitted filename: Response to reviewers - Statins+AHT - 20 01 16.docx

Click here for additional data file.^{(28KB, docx)}

Data Availability Statement

[pone.0229541.ref001] 1.Zissimopoulos J.M., et al. The impact of changes in population health and mortality on future prevalence of Alzheimer’s disease and other dementias in the United States. The Journals of Gerontology: Series B, 2018. 73(suppl_1): p. S38–S47. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref002] 2.Chen C. and Zissimopoulos J.M., Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2018. 4: p. 510–520. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref003] 3.Lourida I., et al. Association of Lifestyle and Genetic Risk With Incidence of Dementia. JAMA, 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref004] 4.World Health Organization, Risk reduction of cognitive decline and dementia: WHO guidelines, in Risk reduction of cognitive decline and dementia: WHO guidelines; 2019. 10.1177/1471301217699675 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref005] 5.Livingston G., et al. Dementia prevention, intervention, and care. The Lancet, 2017. 390(10113): p. 2673–2734. [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref006] 6.Zissimopoulos J., Crimmins E. and St Clair P., The Value of Delaying Alzheimer’s Disease Onset. Forum for Health Economics and Policy, 2015. 18(1): p. 25–39. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref007] 7.Chong P.H., Seeger J.D. and Franklin C., Clinically relevant differences between the statins: implications for therapeutic selection. The American Journal of Medicine, 2001. 111(5): p. 390–400. 10.1016/s0002-9343(01)00870-1 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref008] 8.Kandiah N. and Feldman H.H., Therapeutic potential of statins in Alzheimer's disease. Journal of the Neurological Sciences, 2009. 283(1): p. 230–234. [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref009] 9.Reed B., et al. Low HDL and High LDL Serum Cholesterol Are Associated With Cerebral Amyloidosis. JAMA Neurology, 2014. 71(2): p. 195 10.1001/jamaneurol.2013.5390 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref010] 10.Lesser G., et al. Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles. Current Alzheimer Research, 2011. 8(3): p. 303 10.2174/156720511795563755 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref011] 11.Petanceska S.S., et al. Statin therapy for Alzheimer’s disease. Journal of Molecular Neuroscience, 2002. 19(1–2): p. 155–161. 10.1007/s12031-002-0026-2 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref012] 12.Refolo L.M., et al. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiology of Disease, 2001. 8(5): p. 890–899. 10.1006/nbdi.2001.0422 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref013] 13.Richardson K., et al. Statins and cognitive function: a systematic review. Annals of Internal Medicine, 2013. 159(10): p. 688–697. 10.7326/0003-4819-159-10-201311190-00007 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref014] 14.Shepardson N.E., Shankar G.M. and Selkoe D.J., Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Archives of Neurology, 2011. 68(11): p. 1385–1392. 10.1001/archneurol.2011.242 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref015] 15.Schultz B.G., Patten D.K. and Berlau D.J., The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Translational Neurodegeneration, 2018. 7(1): p. 5. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref016] 16.Zissimopoulos J.M., et al. Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease. JAMA Neurology, 2017. 74(2): p. 225–232. 10.1001/jamaneurol.2016.3783 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref017] 17.Redelmeier D.A., Manzoor F. and Thiruchelvam D., Association Between Statin Use and Risk of Dementia After a Concussion. JAMA Neurology, 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref018] 18.Haag M.D., et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. Journal of Neurology, Neurosurgery & Psychiatry, 2009. 80(1): p. 13–17. [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref019] 19.Jick H., et al. Statins and the risk of dementia. The Lancet, 2000. 356(9242): p. 1627–1631. [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref020] 20.Li G., et al. Age‐Varying Association Between Statin Use and Incident Alzheimer's Disease. Journal of the American Geriatrics Society, 2010. 58(7): p. 1311–1317. 10.1111/j.1532-5415.2010.02906.x [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref021] 21.Lin F.-C., et al. Early Statin Use and the Progression of Alzheimer Disease: A Total Population-Based Case-Control Study. Medicine, 2015. 94(47): p. e2143 10.1097/MD.0000000000002143 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref022] 22.Wolozin B., et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Medicine, 2007. 5(1): p. 1. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref023] 23.Geifman N., et al. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. Alzheimer's Research & Therapy, 2017. 9(1): p. 10. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref024] 24.Geifman N., et al. Data-driven identification of endophenotypes of Alzheimer’s disease progression: implications for clinical trials and therapeutic interventions. Alzheimer's Research & Therapy, 2018. 10(1): p. 4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref025] 25.Li G., et al. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults. Neurology, 2017. 89(12): p. 1251–1255. 10.1212/WNL.0000000000004392 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref026] 26.Li G., et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology, 2007. 69(9): p. 878–885. 10.1212/01.wnl.0000277657.95487.1c [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref027] 27.Rouch L., et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs, 2015. 29(2): p. 113–130. 10.1007/s40263-015-0230-6 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref028] 28.Marpillat N.L., et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. Journal of Hypertension, 2013. 31(6): p. 1073–1082. 10.1097/HJH.0b013e3283603f53 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref029] 29.Peters R., et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. The Lancet Neurology, 2008. 7(8): p. 683–689. 10.1016/S1474-4422(08)70143-1 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref030] 30.van Charante E.P.M., et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. The Lancet, 2016. 388(10046): p. 797–805. [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref031] 31.Miners J., et al. Angiotensin‐converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE‐1 to cerebral amyloid angiopathy. Neuropathology and Applied Neurobiology, 2008. 34(2): p. 181–193. 10.1111/j.1365-2990.2007.00885.x [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref032] 32.Miners S., et al. Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. American Journal of Translational Research, 2009. 1(2): p. 163 [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref033] 33.Miners J.S., et al. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. Journal of Neuropathology & Experimental Neurology, 2011. 70(11): p. 944–959. [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref034] 34.Kehoe P.G., et al. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology. Alzheimer's Research & Therapy, 2016. 8(1): p. 50. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref035] 35.Kehoe P.G., The coming of age of the angiotensin hypothesis in Alzheimer's disease–progress towards disease prevention and treatment? Journal of Alzheimer's Disease, 2018. 62(3). [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref036] 36.Kehoe P.G. and Wilcock G.K., Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer's disease? The Lancet Neurology, 2007. 6(4): p. 373–378. 10.1016/S1474-4422(07)70077-7 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref037] 37.Kehoe P.G., Miners S. and Love S., Angiotensins in Alzheimer's disease–friend or foe? Trends in Neurosciences, 2009. 32(12): p. 619–628. 10.1016/j.tins.2009.07.006 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref038] 38.Wharton W., et al. Neurofibrillary Tangles and Conversion to Mild Cognitive Impairment with Certain Antihypertensives. Journal of Alzheimer's Disease, 2019(Preprint): p. 1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref039] 39.Wharton W., et al. Modulation of Renin‐Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease. Journal of the American Geriatrics Society, 2015. 63(9): p. 1749–1756. 10.1111/jgs.13627 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref040] 40.Hajjar I., et al. Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Archives of Neurology, 2012. 69(12): p. 1632–1638. 10.1001/archneurol.2012.1010 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref041] 41.Hajjar I., et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society, 2013. 61(2): p. 194–201. 10.1111/jgs.12100 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref042] 42.Li N.-C., et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ, 2010. 340: p. b5465 10.1136/bmj.b5465 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref043] 43.Evans C.E., et al. Exploring ACE-2 as a novel therapeutic target for Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018. 14(7): p. P1659. [Google Scholar]

[pone.0229541.ref044] 44.Barthold D., et al. The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity. PLOS ONE, 2018. 13(11). [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref045] 45.Neuman P. and Jacobson G., Medicare Advantage Checkup. The New England Journal of Medicine, 2018. 379(22): p. 2163–2172. 10.1056/NEJMhpr1804089 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref046] 46.Li P., Kim M.M. and Doshi J.A., Comparison of the performance of the CMS Hierarchical Condition Category (CMS-HCC) risk adjuster with the Charlson and Elixhauser comorbidity measures in predicting mortality. BMC Health Services Research, 2010. 10(1): p. 1. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref047] 47.Bonito A., et al. Creation of new race-ethnicity codes and socioeconomic status (SES) indicators for Medicare beneficiaries. 2008, Agency for Healthcare Research and Quality, and Center for Medicare and Medicaid Services: Rockville, MD. [Google Scholar]

[pone.0229541.ref048] 48.Aitken M., et al. Medicines use and spending in the US: a review of 2016 and outlook to 2021. Parsippany: IMS Institute for Healthcare Informatics, 2016. [Google Scholar]

[pone.0229541.ref049] 49.Long D. Global Generic and Biosimilars Trends and Insights in Association for Accesible Medicines. 2018. IQVIA. [Google Scholar]

[pone.0229541.ref050] 50.Luvai A., et al. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clinical Medicine Insights: Cardiology, 2012. 6: p. CMC. S4324. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref051] 51.White C.M., A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. The Journal of Clinical Pharmacology, 2002. 42(9): p. 963–970. [PubMed] [Google Scholar]

[pone.0229541.ref052] 52.Ferdinand K.C., et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. The American Journal of Cardiology, 2006. 97(2): p. 229–235. 10.1016/j.amjcard.2005.08.026 [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref053] 53.Flockhart, D.A. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine 2007 September 1, 2019]; Available from: https://drug-interactions.medicine.iu.edu

[pone.0229541.ref054] 54.Benedet A.L., et al. CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem. Neurology Genetics, 2018. 4(1): p. e216 10.1212/NXG.0000000000000216 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref055] 55.ALZGENE. Chromosome 10: Location of Published AD Candidate Genes. 2019 September 1, 2019]; Available from: http://www.alzgene.org/chromo.asp?c=10

[pone.0229541.ref056] 56.Wang D., et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. The Pharmacogenomics Journal, 2011. 11(4): p. 274 10.1038/tpj.2010.28 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref057] 57.McGraw J. and Waller D., Cytochrome P450 variations in different ethnic populations. Expert opinion on drug metabolism & toxicology, 2012. 8(3): p. 371–382. [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref058] 58.Jacobsen W., et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metabolism and Disposition, 1999. 27(2): p. 173–179. [PubMed] [Google Scholar]

[pone.0229541.ref059] 59.Xu J., et al. Graded perturbations of metabolism in multiple regions of human brain in Alzheimer's disease: Snapshot of a pervasive metabolic disorder. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2016. 1862(6): p. 1084–1092. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0229541.ref060] 60.Vaughan C.J. and Gotto A.M. Jr, Update on statins: 2003. Circulation, 2004. 110(7): p. 886–892. 10.1161/01.CIR.0000139312.10076.BA [DOI] [PubMed] [Google Scholar]

[pone.0229541.ref061] 61.Deane, R., et al., Clearance of amyloid-β peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 2009. 8(1): p. 16–30. [DOI] [PMC free article] [PubMed]

[pone.0229541.ref062] 62.Nasrallah I.M., et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA, 2019. 322(6): p. 524–534. 10.1001/jama.2019.10551 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Association of combination statin and antihypertensive therapy with reduced Alzheimer’s disease and related dementia risk

Douglas Barthold

Geoffrey Joyce

Roberta Diaz Brinton

Whitney Wharton

Patrick Gavin Kehoe

Julie Zissimopoulos

Roles

Abstract

Background

Methods

Findings

Conclusion

Introduction

Methods

Data

Study sample

Table 1. Characteristics of combination statin and AHT users in 2009–2014 Medicare claims data.

Measuring statin and AHT exposure

Study design

Statistical analyses

Results

Fig 1. Adjusted odds ratios of ADRD incidence associated with use of statin-AHT combinations, relative to users of other statin-AHT combinations, with 95% confidence intervals.

Table 2. Adjusted odds ratios of ADRD incidence associated with use of statin-AHT combinations, relative to users of other statin-AHT combinations.

Discussion

Fig 2. Percent of Medicare beneficiaries with use of selected statin and antihypertensive prescription drugs, 2007–2014.

Conclusion

Supporting information

Data Availability

Funding Statement

References

Decision Letter 0

Tarek K Rajji

Roles

Author response to Decision Letter 0

Decision Letter 1

Tarek K Rajji

Roles

Acceptance letter

Tarek K Rajji

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases